Cortexyme (CRTX) Stock Chart & Stock Price History → weirdest stock market marches on (From DTI) (Ad) Free CRTX Stock Alerts $0.92 -0.04 (-4.17%) (As of 05/7/2024 ET) Add Compare Share Share ChartStock AnalysisChartCompetitorsFinancialsInsider TradesSocial MediaStock AnalysisChartCompetitorsFinancialsInsider TradesSocial Media Cortexyme Stock Price Performance5 Day Performance-4.17%1 Month Performance-10.24%3 Month Performance-28.63%6 Month Performance-4.17%Year-To-Date Performance-12.38%1 Year Performance-41.40% Receive CRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter Email Address Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. CRTX Stock Chart for Tuesday, May, 7, 2024 CRTX Chart by TradingView Cortexyme Share Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization05/06/2024$0.99$0.99$0.99$0.9249,304 shs$29.70 million05/03/2024$0.96$0.96$1.07$0.93105,089 shs$28.95 million05/02/2024$1.07$0.96-10.28%$1.07$0.93104,589 shs$28.95 million05/01/2024$1.06$1.07+1.42%$1.12$1.0596,568 shs$32.26 million04/30/2024$1.06$1.06$1.10$1.0525,698 shs$58.79 million04/29/2024$1.06$1.06-0.47%$1.10$1.0525,698 shs$31.81 million Get the Latest News and Ratings for CRTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter. 04/26/2024$1.06$1.03-2.83%$1.08$1.0393,060 shs$31.06 million04/25/2024$1.11$1.06-4.50%$1.12$1.0591,171 shs$31.96 million04/24/2024$1.06$1.11+4.72%$1.11$1.04129,361 shs$33.47 million04/23/2024$1.05$1.06+0.95%$1.10$1.0057,652 shs$31.96 million04/22/2024$1.05$1.05$1.07$1.0297,247 shs$31.66 million04/19/2024$1.06$1.05-0.94%$1.07$1.0297,247 shs$31.66 million04/18/2024$1.00$1.06+6.00%$1.07$0.9880,573 shs$31.96 million04/17/2024$1.01$1.00-0.50%$1.02$0.96107,929 shs$30.15 million04/16/2024$1.01$1.01$1.05$0.9576,138 shs$30.30 million04/15/2024$0.94$1.01+6.59%$1.05$0.9576,138 shs$30.30 million04/12/2024$1.00$1.00$1.07$0.9774,829 shs$30.15 million04/11/2024$0.99$1.00+1.01%$1.07$0.9774,828 shs$30.15 million04/10/2024$1.04$0.99-4.81%$1.05$0.9984,422 shs$29.85 million04/09/2024$1.95$1.04-46.67%$1.05$1.0118,739 shs$31.36 million04/08/2024$1.03$1.95+90.24%$1.97$1.86272,200 shs$58.79 million04/05/2024$1.04$1.04$1.04$1.0144,995 shs$31.36 million04/04/2024$1.05$1.04-0.95%$1.04$1.0144,995 shs$31.36 million04/03/2024$1.09$1.05-3.67%$1.11$1.0351,435 shs$31.66 million04/02/2024$1.06$1.09+2.83%$1.14$1.05109,138 shs$32.87 million04/01/2024$1.06$1.06$1.13$1.0551,834 shs$31.96 million03/29/2024$1.06$1.06$1.13$1.0551,834 shs$31.96 million03/28/2024$1.13$1.06-6.19%$1.13$1.0551,744 shs$31.96 million03/27/2024$1.13$1.13$1.25$1.1267,069 shs$34.07 million03/26/2024$1.20$1.13-5.83%$1.25$1.1266,905 shs$34.07 million03/25/2024$1.20$1.20$1.22$1.1816,300 shs$36.18 million03/22/2024$1.17$1.20+2.56%$1.22$1.1816,298 shs$36.18 million03/21/2024$1.21$1.17-3.31%$1.23$1.1437,737 shs$35.28 million03/20/2024$1.19$1.21+1.68%$1.23$1.1636,418 shs$36.48 million03/19/2024$1.19$1.19$1.25$1.1459,267 shs$35.88 million03/18/2024$1.16$1.19+2.59%$1.25$1.1459,214 shs$35.88 million03/15/2024$1.18$1.16-1.69%$1.23$1.1422,862 shs$34.98 million03/14/2024$1.18$1.18$1.25$1.1558,807 shs$35.58 million03/13/2024$1.20$1.18-1.67%$1.25$1.1558,807 shs$35.58 million03/12/2024$1.17$1.20+3.00%$1.25$1.1764,824 shs$36.18 millionweirdest stock market marches on (Ad)For the last few months, Graham Lindman has been urging investors to ignore virtually every stock on the exchange and only focus on the handful of “Apex Stocks” that produce all the wealth. And he sure seems to be right! Because while we’re in an extremely bullish market, it’s not because most companies are doing that well. It’s because a handful of wealth generating juggernauts are yanking the market to all time highs. That’s why this headline called it the “Weirdest bull market”Graham is hosting a “tell all” workshop about his Apex Indicator here03/11/2024$1.17$1.17$1.23$1.0862,843 shs$35.13 million03/08/2024$1.17$1.16-0.85%$1.25$1.1440,440 shs$34.98 million03/07/2024$1.21$1.17-3.31%$1.27$1.1618,544 shs$35.28 million03/06/2024$1.21$1.21$1.22$1.1627,137 shs$36.48 million03/05/2024$1.28$1.21-5.47%$1.22$1.1627,090 shs$36.48 million03/04/2024$1.28$1.28$1.33$1.2593,596 shs$38.59 million03/01/2024$1.34$1.30-2.99%$1.37$1.3057,121 shs$39.20 million02/29/2024$1.34$1.34$1.40$1.31164,572 shs$40.40 million02/28/2024$1.29$1.34+3.88%$1.40$1.31164,571 shs$40.40 million02/27/2024$1.33$1.29-3.01%$1.42$1.28118,588 shs$38.90 million02/26/2024$1.33$1.33$1.36$1.2736,077 shs$40.10 million02/23/2024$1.30$1.33+2.31%$1.36$1.2736,026 shs$40.10 million02/22/2024$1.35$1.30-3.70%$1.36$1.3022,649 shs$39.20 million02/21/2024$1.28$1.35+5.47%$1.41$1.27109,330 shs$40.70 million02/20/2024$1.28$1.28$1.32$1.2374,289 shs$38.59 million02/19/2024$1.28$1.28$1.32$1.2374,289 shs$38.59 million02/16/2024$1.30$1.28-1.54%$1.32$1.2374,289 shs$38.59 million02/15/2024$1.19$1.30+9.24%$1.34$1.28100,322 shs$39.20 million02/14/2024$1.30$1.19-8.46%$1.30$1.1945,192 shs$35.88 million02/13/2024$1.30$1.30$1.32$1.2739,797 shs$39.20 million02/12/2024$1.30$1.30$1.34$1.2762,117 shs$39.20 million02/09/2024$1.30$1.30$1.34$1.1990,234 shs$39.20 million02/08/2024$1.29$1.30+0.85%$1.34$1.1989,823 shs$39.20 million02/07/2024$1.34$1.29-3.81%$1.32$1.2632,403 shs$38.87 million02/06/2024$1.33$1.34+0.75%$1.39$1.2855,279 shs$40.40 million Related Companies: IN8bio Stock Price Chart Protara Therapeutics Stock Price Chart MiNK Therapeutics Stock Price Chart Surrozen Stock Price Chart NKGen Biotech Stock Price Chart Achilles Therapeutics Stock Price Chart Pluri Stock Price Chart Estrella Immunopharma Stock Price Chart Brainstorm Cell Therapeutics Stock Price Chart SAB Biotherapeutics Stock Price Chart Receive CRTX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:CRTX) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsObama’s Forever Term [exposed]Porter & CompanyThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortexyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.